Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Idera Pharmaceuticals, Inc.
Adi Diab; Paolo A Ascierto; Michele Maio; Reham Abdel-Wahab; Sylvie Negrier; Laurent Mortier; Petr Arenberger; Stephane Dalle; Ivana Krajsova; Luis de la Cruz; Marie-Therese Leccia; Michele Guida; Celeste Lebbe; Jean-Jacques Grob; Marcus O Butler; Gino K In; Carmen Loquai; John W T Walker; Victoria Atkinson; Ellen Kapiteijn; Sebastian Haferkamp; Srinivas Chunduru; Shahram Rahimian; Massimo Guidoboni; Caroline Robert